ClinicalTrials.gg
AvailableNCT07582874Updated Nov 10, 2026

An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric Hypoglycemia

An expanded access record providing Avexitide in Post-bariatric Hypoglycemia, sponsored by Amylyx Pharmaceuticals Inc.. Available at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Amylyx Pharmaceuticals Inc. · Expanded access

Updated Nov 10, 20266 sites addedGo to Updates ↓
Study type
Expanded access
Access type
Intermediate-size population
Ages
18 Years and older
Sex
All
01

Study summary

The Expanded Access Program will provide access to avexitide for people with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) who meet the eligibility criteria for this program. The safety of avexitide and patient treatment experience will be monitored during this program.

02

Conditions studied

  • Post-bariatric Hypoglycemia

Browse trials for

Keywords

  • AVX
  • avexitide
  • PBH
  • post-bariatric hypoglycemia
  • hypoglycemia post bariatric surgery
  • reactive hypoglycemia
  • hypoglycemia
  • low blood sugar
  • Roux-en-Y gastric bypass (RYGB)
  • Roux-en-Y gastric bypass
  • Roux-en-Y
  • RYGB
  • gastric bypass
  • LUCIDITY
  • PREVENT
  • exendin
  • exendin 9-39
  • exendin 939
03

In context

Hypoglycemia

706 studies on the registry are indexed under Hypoglycemia; 94 are open to participants now.

Browse Hypoglycemia studies →

Lead sponsor

Amylyx Pharmaceuticals Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Eligibility criteria

Patients in this EAP will be eligible in one of two categories (Category A and Category B) as defined below:

  • Category A: Individuals who have completed the LUCIDITY trial through the Week 48 OLE Part B end-of-treatment visit on avexitide.
  • Category B: Individuals who participated in previous avexitide clinical trials conducted in PBH following RYGB; or documented LUCIDITY participants who signed ICF and were eligible for LUCIDITY based on screening and run-in, but were unable to be randomized due to completion of recruitment.

Key Inclusion Criteria:

Applicable to all patients:

  • Male or female, at least 18 years of age; able to understand the purpose and risks of the program, and provides written to participate.
  • Not eligible for or otherwise able to obtain access to avexitide via a clinical trial, and does not have access to satisfactory, alternative treatment options.
  • If female, cannot be breastfeeding or lactating, and if of must agree to use a highly effective method of during EAP participation. A negative urine pregnancy test is required at time of entry.
  • If male, must agree to use a highly effective method of birth control during EAP participation.

For Category A:

  • Have completed the LUCIDITY trial through the Week 48 OLE Part B end-of-treatment visit on avexitide.

For Category B:

  • Have clinical diagnosis of PBH, and underwent documented RYGB ≥ 12 months prior to EAP eligibility assessment.
  • Has (BMI) of up to 40 kg/m2.
  • Treating physician confirmation of either participation in previous avexitide clinical trials conducted in PBH following RYGB; or documented LUCIDITY participant who signed ICF and was eligible for LUCIDITY based on screening and run-in, but was unable to be randomized due to completion of recruitment.

Key Exclusion Criteria:

Applicable to all patients:

  • Use of GLP-1 receptor agonists, glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor dual agonists, and other GLP-1 receptor agonist combination therapies.
  • Presence of any condition which, per the judgment of the treating physician, may preclude the patient from safe treatment.

For Category B:

  • Have received another drug for any indication within 5 half-lives of that drug or have participated in another interventional clinical study within 30 days prior to entry visit.
  • History of upper GI surgery affecting RYGB anatomy or function, other than RYGB.
  • Any known or suspected allergy to the investigational medicinal product (avexitide) or any related product (e.g., exenatide).
  • Abnormal liver function defined as and/or ALT > 5 times the and/or level >3 times the upper limit of the normal within 12 weeks from entry.
  • Renal impairment, defined as an estimated (eGFR) \<30 mL/min/1.73 m2 within 12 weeks from entry.
  • History or presence of insulinoma or other cause of endogenous hyperinsulinism other than PBH.
  • Presence of acute or chronic pancreatitis, history of idiopathic acute pancreatitis, or pancreatic cancer.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Access details

Study type
Expanded access
Access type
Intermediate-size population

Available treatment

  • 90 mg subcutaneous injection once per day at least one hour prior to first meal of the day.

06

Where to request access

10 of 10 sites recruiting
  • Stanford Health Care - Endocrinology Clinic
    Stanford, California 94304, United States
    Available
    • Alaina Adamos · Contactaadamos@stanford.edu · 925-858-2390
    • Marilyn Tan · Principal investigator
  • Hanson Diabetes Center
    Port Charlotte, Florida 33952-6722, United States
    Available
    • Jay Cadorna · Contactjay@hansoncrc.com · 941-764-9110
    • Lenita Hanson · Principal investigator
  • Georgia Clinical Research
    Lawrenceville, Georgia 30044, United States
    Available
    • Sidnei Gibson · Contactsidneig.gcr@gmail.com · 678-822-5581
    • George Rafeedie · Principal investigator
  • Cotton-O'Neil Diabetes and Endocrinology Center
    Topeka, Kansas 66606-2806, United States
    Available
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Available
  • Joslin Diabetes Center
    Boston, Massachusetts 02215-5306, United States
    Available
  • Centricity Research Morehead City Multispecialty
    Morehead City, North Carolina 28557-3126, United States
    Available
  • Endocrine and Psychiatry Center
    Houston, Texas 77095-2856, United States
    Available
  • Southern Endocrinology and Diabetes Associates
    Mesquite, Texas 75149, United States
    Available
  • Diabetes and Glandular Disease Clinic
    San Antonio, Texas 78229-4801, United States
    Available
07

Updates

1 registry update since Sep 25, 2026
Sites
6 sites added
Show 6 added (6 United States)
  • Stanford Health Care - Endocrinology Clinic · Stanford, United States
  • Hanson Diabetes Center · Port Charlotte, United States
  • Georgia Clinical Research · Lawrenceville, United States
  • Cotton-O'Neil Diabetes and Endocrinology Center · Topeka, United States
  • Brigham and Women's Hospital · Boston, United States
  • Endocrine and Psychiatry Center · Houston, United States
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    6 sites added
    Show 6 added (6 United States)
    • Stanford Health Care - Endocrinology Clinic · Stanford, United States
    • Hanson Diabetes Center · Port Charlotte, United States
    • Georgia Clinical Research · Lawrenceville, United States
    • Cotton-O'Neil Diabetes and Endocrinology Center · Topeka, United States
    • Brigham and Women's Hospital · Boston, United States
    • Endocrine and Psychiatry Center · Houston, United States
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

08

Registry details

Key details

Study ID
NCT07582874
Lead sponsor
Amylyx Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
May 13, 2026
Last update
Nov 10, 2026

Study contacts

Medical Director, Amylyx Pharmaceuticals
Contact
MedInfo@amylyx.com
1-857-575-7007
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion